Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240944 | 1.00 | CYP3A4 (0.56) | CYP3A4MAPK1ABCB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8247946 | 1.00 | CYP3A4 (0.56) | CYP3A4MAPK1ABCB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13508832 | 1.00 | CYP3A4 (0.56) | CYP3A4MAPK1ABCB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15918781 | 1.00 | CYP3A4 (0.56) | CYP3A4MAPK1ABCB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14404263 | 1.00 | CYP3A4 (0.56) | CYP3A4MAPK1ABCB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8249233 | 1.00 | CYP3A4 (0.56) | CYP3A4MAPK1ABCB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13508834 | 1.00 | CYP3A4 (0.56) | CYP3A4MAPK1ABCB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13002360 | 0.92 | CYP3A4 (0.62) | CYP3A4MAPK1ABCB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14700160 | 0.92 | CYP3A4 (0.54) | CYP3A4MAPK1ABCB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16160606 | 0.91 | CYP3A4 (0.53) | CYP3A4MAPK1ABCB1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668176-B1 | A NOVEL PROCESS FOR SYNTHESIS OF POLYPHENOLS | SPHAERA PHARMA PTE LTD (SG) | 2017-05-17 | — | — | EP | disclosed |
| US-9428482-B2 | Process for synthesis of polyphenols | SPHAERA PHARMA PTE. LTD. (SG) | 2016-08-30 | — | — | US | disclosed |
| US-20160039781-A1 | NOVEL ANALOGUES OF EPICATECHIN AND RELATED POLYPHENOLS | SPHAERA PHARMA PVT. LTD. (SG) | 2016-02-11 | — | — | US | disclosed |
| US-9187448-B2 | Flavonoid compounds | CARDERO THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9060997-B2 | Antifolate compounds for the treatment of melanoma | UNIVERSIDAD DE MURCIA (ES) | 2015-06-23 | — | — | US | disclosed |
| WO-2014162320-A2 | NOVEL ANALOGUES OF EPICATECHIN AND RELATED POLYPHENOLS | SPHAERA PHARMA PVT. LTD. (IN) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256741-A1 | FLAVONOID COMPOUNDS | CARDERO THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140031421-A1 | NOVEL PROCESS FOR SYNTHESIS OF POLYPHENOLS | SPHAERA PHARMA PTE. LTD. (SG) | 2014-01-30 | — | — | US | disclosed |
| WO-2013022846-A2 | FLAVONOID COMPOUNDS | CARDERO THERAPEUTICS, INC. (US) | 2013-02-14 | — | — | WO | disclosed |
| US-20100279971-A1 | ANTIFOLATE COMPOUNDS FOR THE TREATMENT OF MELANOMA | UNIVERSIDAD DE MURCIA (ES) | 2010-11-04 | — | — | US | disclosed |
| US-7268240-B2 | Synthetic methods for polyphenols | MARS, INC. | 2007-09-11 | — | — | US | disclosed |
| WO-2007002851-A2 | THERMALLY-PROCESSED COCOA PRODUCTS USEFUL FOR VASCULAR HEALTH IMPROVEMENT | MARS, INCORPORATED (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031421-A1 | NOVEL PROCESS FOR SYNTHESIS OF POLYPHENOLS | COMT, NQO1, SPR | CYP3A4 48/4885MAPK1 1219/4885ABCB1 3765/4885 |
| US-20140256741-A1 | FLAVONOID COMPOUNDS | FIS1, TFAM, MFN2 | CYP3A4 3740/4885MAPK1 943/4885ABCB1 3737/4885 |
| US-20100279971-A1 | ANTIFOLATE COMPOUNDS FOR THE TREATMENT OF MELANOMA | RECQL, MTX1, RRM2B | CYP3A4 1857/4885MAPK1 3173/4885ABCB1 841/4885 |
| US-20160039781-A1 | NOVEL ANALOGUES OF EPICATECHIN AND RELATED POLYPHENOLS | PGC, TEAD3, TEAD4 | CYP3A4 518/4885MAPK1 2613/4885ABCB1 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.